[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.

Community pharmacies now have access to an affordable, comprehensive solution that encompasses both training and certification needs. RxTechExam’s education program is recognized by PTCB, the premier ...

Brown Convention Center - Exhibit Halls A B About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...

Brown Convention Center A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded. About TScan ...

Presentation Title: Development of a Surface Engineered Lentiviral Vector for In Vivo Generation of CD22-Directed CAR T Cells Presenting Author: Jeffrey Teoh, Ph.D. Poster Number: 1145 Presentation ...

Poster presentation details: Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity ...

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC) Lead Author: ...

Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics) ...

Mr. Crecca commented, “I am excited to join NEXGEL’s Scientific Advisory Board and collaborate with a talented group of individuals to support the development of new therapies leveraging the Company’s ...

Pankaj Mohan, Founder and Chief Executive Officer of Sonnet commented, “We are grateful for NJEDA's continued support of the biotechnology industry and to be one of the recipients to benefit from the ...

As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025.